These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 14571839)

  • 1. [Dendritic cell therapy for malignant glioma].
    Yamanaka R; Homma J; Yajima N; Tsuchiya N; Tanaka R
    No To Shinkei; 2003 Sep; 55(9):771-80. PubMed ID: 14571839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cell-based glioma immunotherapy (review).
    Yamanaka R; Yajima N; Abe T; Tsuchiya N; Homma J; Narita M; Takahashi M; Tanaka R
    Int J Oncol; 2003 Jul; 23(1):5-15. PubMed ID: 12792771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Peptide vaccination therapy for malignant glioma].
    Yamanaka R; Itoh K
    Brain Nerve; 2007 Mar; 59(3):251-61. PubMed ID: 17370651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel immunotherapeutic approaches to glioma.
    Yamanaka R
    Curr Opin Mol Ther; 2006 Feb; 8(1):46-51. PubMed ID: 16506525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cell vaccines.
    Yamanaka R; Kajiwara K
    Adv Exp Med Biol; 2012; 746():187-200. PubMed ID: 22639169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell- and peptide-based immunotherapeutic approaches for glioma.
    Yamanaka R
    Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cell vaccination in patients with malignant gliomas: current status and future directions.
    de Vleeschouwer S; Rapp M; Sorg RV; Steiger HJ; Stummer W; van Gool S; Sabel M
    Neurosurgery; 2006 Nov; 59(5):988-99; discussioin 999-1000. PubMed ID: 17143233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cell-based immunotherapy for malignant gliomas.
    Akasaki Y; Black KL; Yu JS
    Expert Rev Neurother; 2005 Jul; 5(4):497-508. PubMed ID: 16026233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial.
    Yamanaka R; Homma J; Yajima N; Tsuchiya N; Sano M; Kobayashi T; Yoshida S; Abe T; Narita M; Takahashi M; Tanaka R
    Clin Cancer Res; 2005 Jun; 11(11):4160-7. PubMed ID: 15930352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic-cell- and peptide-based vaccination strategies for glioma.
    Yamanaka R
    Neurosurg Rev; 2009 Jul; 32(3):265-73; discussion 273. PubMed ID: 19214609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
    Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
    Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cellular immunotherapy for malignant glioma].
    Okamoto Y; Yamashita J
    Nihon Rinsho; 2005 Sep; 63 Suppl 9():557-62. PubMed ID: 16201581
    [No Abstract]   [Full Text] [Related]  

  • 13. Galectin-1 and immunotherapy for brain cancer.
    Verschuere T; De Vleeschouwer S; Lefranc F; Kiss R; Van Gool SW
    Expert Rev Neurother; 2011 Apr; 11(4):533-43. PubMed ID: 21469926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination.
    Liu G; Black KL; Yu JS
    Expert Rev Vaccines; 2006 Apr; 5(2):233-47. PubMed ID: 16608423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas.
    Newcomb EW; Demaria S; Lukyanov Y; Shao Y; Schnee T; Kawashima N; Lan L; Dewyngaert JK; Zagzag D; McBride WH; Formenti SC
    Clin Cancer Res; 2006 Aug; 12(15):4730-7. PubMed ID: 16899624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell adoptive immunotherapy of newly diagnosed gliomas.
    Plautz GE; Miller DW; Barnett GH; Stevens GH; Maffett S; Kim J; Cohen PA; Shu S
    Clin Cancer Res; 2000 Jun; 6(6):2209-18. PubMed ID: 10873070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic activity of ex-vivo generated IFNα-induced monocyte-derived dendritic cells in brain glioma patients.
    Tyrinova TV; Leplina OY; Mishinov SV; Tikhonova MA; Shevela EY; Stupak VV; Pendyurin IV; Shilov AG; Alyamkina EA; Rubtsova NV; Bogachev SS; Ostanin AA; Chernykh ER
    Cell Immunol; 2013; 284(1-2):146-53. PubMed ID: 23973877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
    Fecci PE; Sweeney AE; Grossi PM; Nair SK; Learn CA; Mitchell DA; Cui X; Cummings TJ; Bigner DD; Gilboa E; Sampson JH
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4294-305. PubMed ID: 16857805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of a human leukocyte antigen-A24-restricted antitumor cell with the use of SART-1 peptide and dendritic cells in patients with malignant brain tumors.
    Yoshida S; Tanaka R
    J Lab Clin Med; 2004 Oct; 144(4):201-7. PubMed ID: 15514588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of cytokine-induced killer cells in nude mouse xenograft model.
    Kim HM; Kang JS; Lim J; Kim JY; Kim YJ; Lee SJ; Song S; Hong JT; Kim Y; Han SB
    Arch Pharm Res; 2009 May; 32(5):781-7. PubMed ID: 19471894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.